Home
>
National Drug Code (NDC)
>
Simulect
Simulect - 0078-0331-84 - (basiliximab)
Drug Information of Simulect
| Product NDC: | 0078-0331 |
| Proprietary Name: | Simulect |
| Non Proprietary Name: | basiliximab |
| Active Ingredient(s): | 20 mg/5mL & nbsp; basiliximab |
| Administration Route(s): | INTRAVENOUS |
| Dosage Form(s): | INJECTION, POWDER, FOR SOLUTION |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of Simulect
| Product NDC: | 0078-0331 |
| Labeler Name: | Novartis Pharmaceuticals Corporation |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | BLA103764 |
| Marketing Category: | BLA |
| Start Marketing Date: | 19980512 |
Package Information of Simulect
| Package NDC: | 0078-0331-84 |
| Package Description: | 1 VIAL, SINGLE-USE in 1 CARTON (0078-0331-84) > 5 mL in 1 VIAL, SINGLE-USE |
NDC Information of Simulect
| NDC Code | 0078-0331-84 |
| Proprietary Name | Simulect |
| Package Description | 1 VIAL, SINGLE-USE in 1 CARTON (0078-0331-84) > 5 mL in 1 VIAL, SINGLE-USE |
| Product NDC | 0078-0331 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | basiliximab |
| Dosage Form Name | INJECTION, POWDER, FOR SOLUTION |
| Route Name | INTRAVENOUS |
| Start Marketing Date | 19980512 |
| Marketing Category Name | BLA |
| Labeler Name | Novartis Pharmaceuticals Corporation |
| Substance Name | BASILIXIMAB |
| Strength Number | 20 |
| Strength Unit | mg/5mL |
| Pharmaceutical Classes | Interleukin 2 Receptor Antagonists [MoA],Interleukin 2 Receptor-directed Antibody Interactions [MoA],Interleukin-2 Receptor Blocking Antibody [EPC] |
